Sinobiopharma Applies for Chinese Patent to Develop the Next Generation of Anti-Hypertension Compounds
07 April 2009 - 6:00AM
PR Newswire (US)
-Sinobiopharma to Market the World's First Perindopril in Capsule
Form- NANJING, China, April 6 /PRNewswire-FirstCall/ --
Sinobiopharma, Inc. ("Sinobiopharma", or "the Company") (OTC:SNBP)
(BULLETIN BOARD: SNBP) is pleased to announce that it has applied
for a single Chinese patent for new drug compounds containing
Perindopril, an angiotensin-converting enzyme (ACE) inhibitor used
to treat high blood pressure (hypertension) and heart attack in
people with coronary artery disease. Sinobiopharma is the world's
first manufacturer and marketer of Perindopril in capsule form. The
Company's patent application covers the method of preparation and
stability for new drug compounds containing Perindopril. High blood
pressure is a leading cause of stroke, heart attack and kidney
failure and affects about a billion people worldwide. In China,
incidences of cardiovascular and cerebrovascular disease are on
rise, costing patients about 300 billion yuan (US$37 billion) in
medical expenses each year, of which 30 billion (US$3.7 billion) is
spent directly for the treatment of hypertension (source: China's
Ministry of Health). "High blood pressure affects nearly one in
five Chinese adults during his lifetime (source: State Council of
China). The urgency to bring new medicines to market to treat this
deadly disease is paramount in China and worldwide," said
Sinobiopharma Vice President Xuejun Chen. "As China's first maker
of the next generation of Perindopril, Sinobiopharma comes to
market with significant competitive advantages including lower API
(active pharmaceutical ingredient) costs, an easier-to-swallow
formula, greater efficacy and reduced side effects compared to
earlier versions of the drug. We look forward to launching the next
generation of Perindopril compounds, following confirmation of the
standardization of usage, later this year." Perindopril, used alone
or in combination with other medications to treat high blood
pressure, is the latest generation of a class of medications called
angiotensin-converting enzyme (ACE) inhibitors. It supports
circulation by preventing the production of chemicals that occur
naturally in the body but constrict blood vessels. The Company has
received the Drug Certificate for Perindopril raw material
(Certificate #2007S00493) from the Chinese State Food and Drug
Administration, (SFDA), and is now awaiting GMP Certification. The
Company has submitted its application to China's State Intellectual
Property Office (SIPO) for a Chinese patent for Perindopril and its
new drug compounds and obtained a receiving number (200810242989.1;
"New Drug Compounds Containing Perindopril"). Sinobiopharma
completed clinical trials for the capsule formulation in September
2007. Sinobiopharma has received approval from the SFDA to
manufacture and market its new version of the anti-hypertensive
drug, Perindopril, as well as its API. Prior to SFDA approval of
Sinobiopharma's version, Servier (France) was the only firm to
market Perindopril in China. About Sinobiopharma Sinobiopharma Inc.
is a fully integrated and highly innovative biotechnology company
engaged in the research and development, manufacture and marketing
of biopharmaceutical products in China, the world's fastest growing
pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical
Co. Ltd. in China, the Company's current therapeutic focus is on
anesthesia-assisted agents and cardiovascular drugs. FORWARD
LOOKING STATEMENTS This news release may include "forward-looking
statements" regarding Sinobiopharma, Inc., and its subsidiaries,
business and project plans. Such forward looking statements are
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and section 21E of the United States Securities and
Exchange Act of 1934, as amended, and are intended to be covered by
the safe harbor created by such sections. Where Sinobiopharma, Inc.
expresses or implies an expectation or belief as to future events
or results, such expectation or belief is believed to have a
reasonable basis. However, forward-looking statements are subject
to risks, uncertainties and other factors, which could cause actual
results to differ materially from future results expressed,
projected or implied by such forward-looking statements.
Sinobiopharma, Inc. does not undertake any obligation to update any
forward-looking statement, except as required under applicable law.
DATASOURCE: Sinobiopharma, Inc. CONTACT: Investor Relations of
Sinobiopharma, Inc., +1-877-568-0188 Web Site:
http://www.sinobiopharma.com/
Copyright